Connect Biopharma will proceed with enrollment in the Phase 2 Seabreeze STAT trial of Rademikibart for asthma and COPD after an independent review. The update de-risks the development timeline and supports continued clinical progress for the company's lead asset. With no efficacy or safety data reported, the news is positive but likely limited in near-term market impact.
Connect Biopharma will proceed with enrollment in the Phase 2 Seabreeze STAT trial of Rademikibart for asthma and COPD after an independent review. The update de-risks the development timeline and supports continued clinical progress for the company's lead asset. With no efficacy or safety data reported, the news is positive but likely limited in near-term market impact.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialOverall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
